<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053102</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-100</org_study_id>
    <secondary_id>2016-002652-25</secondary_id>
    <secondary_id>U1111-1190-3490</secondary_id>
    <nct_id>NCT03053102</nct_id>
  </id_info>
  <brief_title>A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
  <official_title>A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of ACH-0144471 in
      currently untreated patients with PNH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change-from-baseline in serum lactate dehydrogenase (LDH) levels</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline in hemoglobin (Hgb)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs), Grade 3 and Grade 4 Adverse Events (AEs), and AEs leading to discontinuation</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 and Grade 4 laboratory abnormalities</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics: Area under the curve (AUC)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics: Time to maximum concentration (Tmax)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacodynamics: Complement pathway biomarkers (AP-Wieslab, factor D, and Bb)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>ACH-0144471</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive ACH-0144471 during the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471</intervention_name>
    <description>ACH-0144471 will be administered to all patients enrolled in the study.</description>
    <arm_group_label>ACH-0144471</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 18 years or older

          -  Currently untreated PNH patients with PNH Type III erythrocyte and/or granulocyte
             clone size ≥ 10% and anemia (Hgb &lt; 12g/dL) with adequate reticulocytosis (as
             determined by the investigator)

          -  Lactate dehydrogenase (LDH) ≥ 1.5X the upper limit of normal (ULN)

          -  Platelets ≥ 50,000/uL without the need for platelet transfusions

          -  Documentation of vaccination for N. meningitidis (quadrivalent ACWY and serogroup B),
             H. influenza, and S. pneumoniae, or willingness to receive vaccinations during the
             screening period

          -  Negative pregnancy test for females prior to dosing and throughout the study

        Exclusion Criteria:

          -  History of a major organ transplant (e.g., heart, lung, kidney, liver) or
             hematopoietic stem cell/marrow transplant

          -  Patients who have received another investigational agent within 30 days or 5
             half-lives of the investigational agent prior to study entry, whichever is greater

          -  Patients who have received eculizumab at any dose or interval within the past 75 days
             before study entry

          -  Patients with known or suspected complement deficiency

          -  Patients with active bacterial infection or clinically significant active viral
             infection, a body temperature &gt; 38°C, or other evidence of infection on Day 1, or
             with a history of febrile illness within 14 days prior to first study drug
             administration

          -  History of meningococcal infection, or a first-degree relative or household contact
             with a history of meningococcal infection

          -  Females who are pregnant, nursing, or planning to become pregnant during the study or
             within 90 days of study drug administration or patients with a female partner who is
             pregnant, nursing, or planning to become pregnant during the study or within 90 days
             of study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Lahey</last_name>
    <email>jlahey@achillion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>February 1, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <keyword>Paroxysmal</keyword>
  <keyword>Hemoglobinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
